97results about "Microorganism libraries" patented technology

To provide: an antigen binding molecule with enhanced uptake of antigen into cells; an antigen binding molecule with an increased number of bonds to an antigen; an antigen binding molecule which can promote the decrease of antigen concentration in blood plasma when administered; and an antigen binding molecule with improved retention in blood plasma.SOLUTION: An antigen binding molecule comprises an antigen binding domain and a human FcRn binding domain, in which the antigen binding activity under two different calcium concentration conditions is different, the antigen binding activity of the antigen binding molecule under low calcium concentration conditions being lower than antigen binding activity under high calcium concentration conditions, and which has binding activity to human FcRn under neutral pH conditions.SELECTED DRAWING: None

The present invention provides an hBCMA-binding polypeptide comprising at least one motif that binds to hBCMA, wherein the peptide has the following structure: [N-terminal portion]-[Helix 1]-[Spacer portion]-[Helix 2]-[C-terminal portion], and the hBCMA-binding motif is the portion [Helix 1]-[Spacer portion]-[Helix 2]. The present invention further provides a pharmaceutical composition comprising the hBCMA-binding polypeptide, and the use of the hBCMA-binding polypeptide or the pharmaceutical composition for use as a medicament, particularly for the treatment or prevention of cancer.

The present disclosure provides a recombinant Salmonella strain having a Type III secretion system (T3SS) comprising mutation which enhance protein expression and production. Additionally, methods and kits for using the recombinant Salmonella strain for producing a protein of interest are provided. Additionally, an optimized medium that increases protein expression in a Salmonella strain having a Type III secretion system (T3SS) is provided.

The present invention provides a method for screening for a candidate peptide capable of binding to a target molecule, the method including the steps of: (1) preparing a plurality of nucleic acid display libraries containing a barcoded peptide-nucleic acid complex, wherein the barcoded peptide-nucleic acid complex contains a nucleic acid moiety and a peptide moiety, the nucleic acid moiety contains a barcode sequence and a nucleic acid sequence encoding the peptide, and the plurality of nucleic acid display libraries are nucleic acid display libraries, each of which is independently produced by translation using a cell-free translation system; (2) mixing the plurality of nucleic acid display libraries to prepare a mixed nucleic acid display library; (3) bringing the mixed nucleic acid display library into contact with the target molecule; and (4) amplifying a nucleic acid corresponding to the nucleic acid moiety of the barcoded peptide-nucleic acid complex bound to the target molecule, using a barcode primer.

Disclosed are compositions and methods for engineered DLL4 proteins. In one aspect, disclosed herein are engineered DLL4 proteins comprising a conservative amino acid substitution at a residue corresponding to residues 28, 107, 143, 194, and 206 as set forth in SEQ ID NO: 1 and further comprising at least one conservative amino acid substitution at residues 256, 257, 271, 280, 301, and 305 as set forth in SEQ ID NO: 1.

The application discloses a hemoglobin camel-derived nanobody and a preparation method and application thereof. The hemoglobin camel-derived nanobody is an amino acid sequence shown in SEQ ID NO: 7, is a hemoglobin camel-derived nanobody specific to hemoglobin derived from a bactrian camel, has small molecules, can easily penetrate, has high specificity, good stability, is easy to produce and transform, has wide application prospects, and can be applied to the fields of biomedical research, clinical diagnosis and treatment and the like.

The present disclosure relates to a modified polypeptide of glutamine synthetase having enhanced activity and a method of producing L-glutamine using the same. Since production of L-glutamine may be increased by using the novel modified polypeptide without a decrease in a growth rate compared to wild-type strains having glutamine synthetase activity, the modified polypeptide may be widely used for mass production of L-glutamine.

The present disclosure provides methods, compositions, and systems for evolving virus-like particles (VLPs) having one or more desired properties such as increased production levels, increased cargo packaging efficiency, and / or increased transduction of particular target cell types of interest. The present disclosure also provides libraries for use in such methods, and methods for producing the libraries. Group specific antigen (gag) proteins comprising nucleocapsid protein variants evolved using the methods described herein are also provided herein. The present disclosure also provides VLPs comprising such gag proteins comprising nucleocapsid protein variants. Polynucleotides, vectors, cells, and kits useful for performing the methods described herein are also provided.

The present invention provides cell vaccine platforms, such as vaccine-immune virus opsonization platforms, for inducing a host immune response, as well as methods for producing and using such cell vaccine platforms. [Solution] Several embodiments provide genetically engineered human cells comprising (a) genomic disruption in at least one human leukocyte antigen (HLA) gene or at least one transcription regulator of an HLA gene, and (b) an exogenous nucleic acid encoding a cell surface protein that binds to a protein expressed on the surface of phagocytic or cytolytic immune cells, or a functional fragment or functional variant of the cell surface protein, wherein the binding results in activation of the phagocytic or cytolytic activity of the immune cells.

The invention relates to a new method for selecting or screening antibodies and antigens from an antibody library together with suitable expression vectors and their use.

We provide a system for screening compounds. [Solution] This application provides beads with covalently attached compounds and covalently attached DNA barcodes, as well as methods for using such beads. The beads have many substantially identical copies of compounds and many substantially identical copies of DNA barcodes. The compounds consist of one or more chemical monomers, and the DNA barcodes take the form of barcode modules, each module enabling the identification of corresponding and corresponding chemical monomers. The nucleic acid barcodes may have a chain-like or orthogonal structure. Methods for sequencing bead-bound nucleic acid barcodes, methods for cleaving compounds from beads, and methods for evaluating the biological activity of released compounds are provided.

Provided herein are engineered Saccharomyces boulardii (S. boulardii) yeasts. The engineered yeasts comprise an exogenous protein encoded by a heterologous agglutinin polynucleotide linked to a target domain polynucleotide encoding a target domain. The target domain is encoded in frame to allow for production of the exogenous protein, and the exogenous protein is displayed on the surface of, or is secreted from, the yeast. Also provided are compositions comprising the engineered yeast, methods of treating a gastrointestinal or proliferative disorder, methods of detecting a gastrointestinal or proliferative disorder within the gastrointestinal tract, and kits for preparing an engineered S. boulardii yeast.

This invention discloses a method for constructing a tomato core membrane-associated protein interaction library based on Gateway technology under Fusarium oxysporum infection conditions and its application, relating to the field of genetic engineering technology. The method includes: using tomato root tissue infected with Fusarium oxysporum as material, extracting total RNA and enriching mRNA; synthesizing first-strand cDNA using Biotin-attB2-Oligo(dT) primers; synthesizing double-stranded cDNA enzymatically; ligating it with a specific double-stranded attB1 adapter; introducing attB1 and attB2 sites at both ends of the cDNA; cloning the cDNA into the donor vector pDONR222 via BP recombination to construct a primary entry library; and recombinating the primary entry library with vectors pGADT7 and pPR3-N via LR recombination to construct a nuclear secondary library and a membrane secondary library, respectively. The constructed libraries have high titers, long insert fragments, and low empty vector rates. This invention also relates to the application of the library in screening the interaction between Fusarium oxysporum effector proteins and tomato nuclear membrane-associated proteins, providing an efficient and specific resource platform for studying plant-pathogen interaction mechanisms.

An extracellular vesicle (EV) associated with a viral vector is provided. The combination of the EV and virus vectors provide widespread and highly efficient transgene expression in lungs, following localized administration, as well as in mucus-covered air-liquid interface (ALI) cultures with primary human bronchial epithelial (HBE) cells and nasal epithelial (HNE) cells.

Compositions and methods for fixing cells or nuclei or extracellular vesicles with dithiobismaleimidoethane (DTME) and subsequent reverse transcription in the cells or nuclei or extracellular vesicles are provided.

This document provides a method for preparing plasmid libraries in accordance with current Good Manufacturing Practice (cGMP) guidelines.

The present application relates to: a novel mutant polypeptide having isopropylmalate synthase activity; and a method for producing L-leucine by using same. L-leucine can be produced at high yield by using the mutant polypeptide according to an embodiment.

A cysteine-directed proximity-driven strategy for the construction of bicyclic peptides from simple natural peptide precursors. This linear to bicycle transformation initiates with rapid cysteine labeling, which then triggers proximity-driven amine-selective cyclization. This bicyclization proceeds rapidly under physiologic conditions, yielding bicyclic peptides with a Cys-Lys-Cys, Lys-Cys-Lys or N-terminus-Cys-Cys stapling pattern. Novel phage libraries of bicyclic peptides and method of use thereof for screening therapeutic proteins.

The present invention is directed to SH3 domain derivatives having a specific binding affinity to a target molecule. In this respect, the invention provides SH3 domain derivatives of nephrocystin (NPHP1) and the Tec kinase. The invention also provides a method for the production of a library comprising recombinant derivatives of NPHP1 or the Tec kinase SH3 domains and a method for selecting from the library one or more derivatives of the SH3 domain of nephrocystin (NPHP1) or the Tec kinase having a specific binding affinity to a target molecule.

Methods and systems for delivery using one or more delivery particles (e.g., virions (e.g., AAV), lipid-based delivery particles, etc.) of one or more cargos (e.g., cargo polypeptides) and subsequent quantification of an abundance of one or more cargos (e.g., proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) using barcodes (e.g, peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g, phage) are provided herein.

Provided herein are methods of producing plasmid libraries according to Current Good Manufacturing Practice (cGMP) guidelines.

This invention belongs to the field of biotechnology, specifically relating to a *Pseudomonas putida* genome insertion site library and its construction method. This invention, for the first time, systematically screened and obtained 17 specific genome insertion sites suitable for *Pseudomonas putida*. The constructed insertion site library covers different expression intensities, filling the gap in existing technologies lacking efficient integration sites for *Pseudomonas putida*, and providing diverse options for personalized expression of target genes. The screened insertion sites are all located in the regions of opposing transcription genes, avoiding interference with the host's basal metabolic network. The recombinant strain exhibits stable growth performance without significant growth inhibition, making it suitable for large-scale industrial applications. The integration method, based on homologous recombination, achieves stable integration of the target gene without plasmid maintenance, avoiding expression instability caused by plasmid loss and copy number fluctuations. It also reduces the continuous use of antibiotics, lowering industrialization costs and environmental risks, and the construction method is simple and efficient.

Provided are methods and compositions for creating an arrayed library of cells. In particular, the methods and compositions provided herein improve the selection and transfer of cells by reducing contamination, increasing throughput, and improving consistency of transfer. Such methods and compositions include automated colony selection employing a solid barrier mounted on an automated apparatus for automatic handling of one or more pick tools. The solid barrier is configured to prevent undesired transfer of cells from a pick tool into the destination receptacle. Such methods and compositions also include acoustic transfer of cells in a high-density media by an acoustic liquid handler. The methods and compositions further include pooling the cells using a bitcode sample pooling scheme for high-throughput sequencing and deconvoluting the obtained nucleic acid sequences to identify the cells from which the sequences originated.

The present invention relates to a method for stabilizing a fast decay component C3bBb complex of a bypass pathway of a complement system as well as a stabilized C3bBb complex and its use.

The present invention provides a CD16a-binding polypeptide comprising at least one motif that binds to CD16a, wherein the polypeptide comprises the following structure: [N-terminal portion]-[Helix 1]-[Spacer portion]-[Helix 2]-[C-terminal portion], and the CD16a-binding motif is the [Helix 1]-[Spacer portion]-[Helix 2] portion. The present invention further provides a pharmaceutical composition comprising the CD16a-binding polypeptide, and the use of the CD16a-binding polypeptide or the pharmaceutical composition as a medicament for use in the treatment or prevention of cancer, particularly multiple myeloma.

This invention provides PD-L1 nanobodies, PD-L2 nanobodies, and bispecific antibodies containing both PD-L1 and PD-L2 nanobodies. These bispecific antibodies can simultaneously block the PD-1 / PD-L1 and PD-1 / PD-L2 pathways. The bispecific antibodies of this invention can restore T cell activity, enhance immune responses, and more effectively improve the inhibitory effect on tumor occurrence and development.

The present disclosure provides scaffold proteins that serve as framework regions for different sets of complementarity determining regions (CDRs) from source antibodies, where the source antibodies bind to different epitopes. The scaffold proteins find use in generating antigen binding polypeptides in single chain fragment variable (scFv) antibody format from a variety of antibodies of interest. These antigen binding polypeptides can have one or more advantageous properties as compared to a source antibody, such as, increased affinity, increased stability, increased expression in a cell, increased yield, etc. The sequence of a scaffold protein has a sequence identity of less than 68% to the sequence of the framework regions of the source antibody.

The present application relates to: a novel mutant polypeptide having isopropylmalate synthase activity; and a method for producing L-leucine by using same. L-leucine can be produced at high yield by using the mutant polypeptide according to an embodiment.

The methods disclosed herein utilize a high-throughput screening assay (GigaAssay) to generate a comprehensive gene activity mutagenesis (MEGA)-mutagenesis profile (Map). These methods can be used to evaluate mutagenesis on any gene under any conditions (e.g., drug therapy) using any assay in cultured mammalian cells. Therefore, the methods provided herein can be used to discover and screen dominant-negative variants and to provide a reliable solution to the problem of identifying pharmacologically active unique variants of proteins. Furthermore, these methods can be integrated into cell-based assays to investigate disease pathogenesis and test promising drugs.

Described herein are methods for identifying immune cell-specific antigens and compositions for use in the methods.